Life, 2021 (1) Background: In clinical settings, data regarding sex are rarely investigated. In women, factors such as body size and composition, hormonal variations, metabolism, and access to care systems and therapy could strongly influence the pharmacological ...
Sarah Allegra +7 more
doaj +1 more source
GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo [PDF]
, 2015 We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner.
Amendola, Donatella +16 more
core +2 more sources
Frontiers in Endocrinology, 2023 ObjectiveHypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied.
Andrea Delbarba +10 more
doaj +1 more source
An Excellent Clinical and Radiological Response Pattern to Pembrolizumab in a Patient With Metastatic Adrenocortical Carcinoma and Lynch Syndrome. [PDF]
IJU Case RepABSTRACT Introduction The prognosis of unresectable metastatic adrenocortical carcinoma is very poor. We report a case of Lynch syndrome accompanying metastatic adrenocortical carcinoma treated with pembrolizumab. Case Presentation A 73‐year‐old woman was diagnosed with left adrenocortical carcinoma and multiple lung, liver, and lymph node metastases ...
Shimozawa Y +9 more
europepmc +2 more sources
Dyslipidemia causes overestimation of plasma mitotane measurements
Endocrinology, Diabetes & Metabolism Case Reports, 2016 Mitotane (o,p′-DDD) is the standard treatment for advanced adrenocortical carcinoma (ACC). Monitoring of plasma mitotane levels is recommended to look for a therapeutic window between 14 and 20mg/L, but its positive predictive value requires optimization.
Angelo Paci +13 more
doaj +1 more source
Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma
Endocrinology, Diabetes & Metabolism Case Reports, 2023 Mitotane is used for treatment of advanced adrenocortical carcinoma. It is administered when the carcinoma is unresectable, metastasized, or at high-risk of recurrence after resection.
Sandra Martens, Bruno Lapauw
doaj +1 more source
Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrations [PDF]
, 2010 <b>Background</b>: Acute phase proteins (APPS) include haptoglobin (Hp), C-reactive protein (CRP) and serum amyloid A (SAA). Increased Hp concentrations may be induced by endogenous or exogenous glucocorticoids in dogs. <b>Objectives&
Angles +36 more
core +1 more source
Methylation status of Vitamin D receptor gene promoter in benign and malignant adrenal tumors [PDF]
, 2015 We previously showed a decreased expression of vitamin D receptor (VDR) mRNA/protein in a small group of adrenocortical carcinoma (ACC) tissues, suggesting the loss of a protective role of VDR against malignant cell growth in this cancer type ...
Cappellesso, Rocco +7 more
core +4 more sources
Persistent isolated hypocortisolism following brief treatment with trilostane [PDF]
, 2008 A 12-year-old male neutered Miniature Poodle with confirmed pituitary-dependent hyperadrenocorticism was treated with trilostane. After three doses, it developed clinical and laboratory changes suggestive of isolated hypocortisolism ('atypical ...
Barker +19 more
core +1 more source
Conventional and novel strategies in the treatment of adrenocortical cancer
Brazilian Journal of Medical and Biological Research, 2000 Adrenocortical carcinoma is a highly malignant neoplasm with an incidence of two per million people per year. Several treatment strategies have resulted in temporary or partial tumor regression but very few cases have attained long survival.
D.E. Schteingart
doaj +1 more source